Acne, characterized by chronic inflammation of the skin, has a multifactorial pathogenesis. Despite the array of available treatments, it remains one of the most prevalent dermatological conditions globally. While primarily affecting adolescents, a noteworthy and escalating number of cases occur in adults, particularly women.
The complex pathogenesis of acne encompasses follicular hyperkeratinization, colonization by Cutibacterium acnes, sebum production, intricate inflammatory processes involving innate and acquired immunity, neuroendocrine mechanisms, and genetic and non-genetic factors. Risk factors include adolescence, familial predisposition, and oily skin.
Although numerous acne treatments exist, ongoing efforts aim to mitigate side effects such as skin irritation, dryness, and photosensitivity, while enhancing efficacy through refined formulations and novel drugs with innovative mechanisms of action. Emerging products target various aspects of acne's multifactorial pathogenesis, offering promising advancements in treatment options.
With the escalating concern over antibiotic resistance, current guidelines advocate for the judicious use of oral antibiotics and emphasize exploring alternative treatments. Isotretinoin stands out as a highly efficacious therapy for acne: it operates by reducing sebaceous gland size, decreasing sebum secretion, regulating cell proliferation and keratinization, while also possessing anti-inflammatory and immunomodulatory properties. Spironolactone also plays an important role in acne treatment; functioning as a synthetic aldosterone receptor antagonist with anti-androgenic attributes. Androgens exert significant physiological effects on the skin, regulating processes such as skin renewal, hair follicle growth, sebaceous gland proliferation, sebum production, and embryogenesis.
Topical therapies serve as viable options for both initial treatment and maintenance of acne. They can be utilized as monotherapy (excluding topical antibiotics) or in combination with other topical or oral products.